Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Rhea-AI Summary

Phio Pharmaceuticals (NASDAQ: PHIO) will present at the Renmark Financial Communications Live Virtual Non-Deal Roadshow on October 28, 2025 at 12:00 PM EST.

CEO and Chairman Robert Bitterman will provide an update on the company's proprietary INTASYL siRNA technology and progress in the ongoing Phase 1b dose-escalation trial of lead compound PH-762 for treatment of skin cancers. The company recently reported positive interim safety and efficacy results from that trial. A live Q&A will follow the presentation and a replay will be available on Renmark's website.

Insights

Clinical and Investor Analyst

Positive interim Phase 1b results and a live update on PH-762 on October 28, 2025 increase informational clarity for stakeholders.

Phio Pharmaceuticals advances its INTASYL platform via the lead compound PH-762, currently in a Phase 1b dose‑escalation trial; the company reported positive interim safety and efficacy results and scheduled a live presentation on October 28, 2025.

The main dependencies are the ongoing Phase 1b trial and the forthcoming live Q&A, which will provide more detail; the disclosed facts do not include numeric endpoints or timing of next clinical readouts, so definitive impact hinges on details shared during the event and future trial disclosures.

Watch the October 28, 2025 presentation and the posted replay for specifics on safety, efficacy measures, and any planned next steps; these items are the immediate, monitorable catalysts given the information provided.

Registration Link Below for October 28, 2025 12 PM EST Presentation and Live Q&A

King of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were reported in the on-going Phase 1b dose escalation clinical trial with the INTASYL compound PH-762 for the treatment of skin cancer.

Phio's presentation and live Q&A will take place on Tuesday, October 28, 2025, at 12:00 PM EST in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.

"All stakeholders, investors, and other individual followers are invited to join this event to learn more about Phio Pharmaceuticals and our continuing pursuit of innovative pathways towards a cancer free future using our INTASYL technology," stated Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.

REGISTER HERE: https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-phio-m4qNBCVz4M

Please Note: If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.

About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL^® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The on-going Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.

For additional information, visit the Company's website, www.phiopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells, the potential for additional potential applications across the INTASYL portfolio, expectations regarding timing of enrollment, and statements regarding our commercial and clinical strategy, development plans and timelines and other future events.  

These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.  Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.  

Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs

Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel: (416)-644-2020 or (212)-812-7680
www.renmarkfinancial.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270981

FAQ

When will Phio Pharmaceuticals (PHIO) present at the Renmark virtual non-deal roadshow?

Phio will present on October 28, 2025 at 12:00 PM EST.

Who from Phio (PHIO) will present the INTASYL and PH-762 update on October 28, 2025?

CEO and Chairman Robert Bitterman will present and host a live Q&A.

What will Phio (PHIO) discuss about PH-762 during the October 28, 2025 presentation?

Phio will update on INTASYL siRNA technology and progress in the ongoing Phase 1b dose-escalation trial of PH-762 for skin cancers, including recent interim safety and efficacy results.

How can investors register for Phio's (PHIO) October 28, 2025 virtual presentation?

Register via the Renmark live registration link provided by the company; if the link fails, copy and paste it into your browser using the latest Google Chrome.

Will a replay of the Phio (PHIO) October 28, 2025 event be available?

Yes. A replay may be accessed on the Renmark Financial Communications website after the live event.

What recent clinical update will Phio (PHIO) likely reference in the October 28, 2025 presentation?

The company recently reported positive interim safety and efficacy results from the Phase 1b trial of PH-762 for skin cancer.